Camosunate 7-13

Camosunate 7–13 (distributed by Geneith Pharmaceuticals) is a age-customized, Artemisinin-based Combination Therapy (ACT) antimalarial specifically formulated for pediatric patients aged 7 to 13 years. It combines two complementary active pharmaceutical ingredients: artesunate and amodiaquine.

• Artesunate: A water-soluble hemisuccinate derivative of artemisinin. Upon administration, it rapidly converts into its active metabolite, dihydroartemisinin (DHA), generating intra-parasitic free radicals in the presence of heme iron. This action yields fast clearance of blood-stage Plasmodium parasites and rapid resolution of clinical fever within hours.

• Amodiaquine: A 4-aminoquinoline antimalarial derivative structurally related to chloroquine. It accumulates in the parasite’s acidic food vacuole and prevents the polymerization of toxic free heme into inert hemozoin. The buildup of toxic heme leads to parasite destruction, providing extended activity to clear residual parasites and prevent recrudescence.

The age-bracketed 7–13 formulation provides precise, pre-measured dosing (100 mg artesunate / 300 mg amodiaquine) tailored specifically to school-aged children, eliminating the need to split or crush adult tablets.

Primary Medical Indications

Camosunate 7–13 is indicated for children aged 7 to 13 years (or weighing approximately 20 to 35 kg) for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Age & Weight Specificity: Always verify that the child falls within the 7 to 13 years age group (or 20–35 kg weight range). Younger children should use lower-strength formulations (e.g., Camosunate 1–6 years or pediatric suspension).

• Transient Adverse Effects: Amodiaquine may occasionally cause mild fatigue, nausea, vomiting, abdominal discomfort, or dizziness. Taking the dose with food or after a light meal helps minimize gastric irritation.

• Hepatic & Hematological Monitoring: Amodiaquine is contraindicated in patients with a known history of severe hepatic dysfunction or baseline blood dyscrasias (e.g., severe leukopenia or neutropenia).

• Re-Dosing Protocol for Vomiting: If the child vomits within 30 minutes of taking a dose, re-administer a full replacement dose. If vomiting occurs between 30 and 60 minutes, re-administer a half dose. Persistent vomiting requires immediate transition to parenteral therapy (e.g., IV or IM artesunate).

• Not for Severe/Complicated Malaria: Contraindicated as monotherapy for severe or complicated malaria (e.g., cerebral malaria, severe anemia, circulatory collapse). Severe cases require immediate emergency hospital admission and intravenous antimalarials.

• Prophylaxis Restriction: Camosunate 7–13 is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.